← Back to Search

Antibiotic

Cefazolin for Broken Arm (SPAS Trial)

N/A
Waitlist Available
Led By Bob Umberhandt, MD
Research Sponsored by Legacy Health System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months post intervention/surgery
Awards & highlights

SPAS Trial Summary

This trial is testing whether giving antibiotics to kids with a broken arm prevents infection.

Eligible Conditions
  • Supracondylar Humerus Fractures
  • Infections

SPAS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months post intervention/surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months post intervention/surgery for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
deep post operative infection
superficial post operative infection

SPAS Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Cefazolin prophylaxisActive Control1 Intervention
Patient will receive 'study drug' which is comprised of weight-based dose of cefazolin mixed in 300 mL of normal saline, which will be delivered by intravenous means at the time of surgery.
Group II: Placebo controlPlacebo Group1 Intervention
Patient will receive 'study drug' which is comprised of 300 mL of normal saline without any medication/antibiotic, which will be delivered by intravenous means at the time of surgery.

Find a Location

Who is running the clinical trial?

Legacy Health SystemLead Sponsor
35 Previous Clinical Trials
2,481 Total Patients Enrolled
Bob Umberhandt, MDPrincipal InvestigatorPhysician within Legacy Health System

Media Library

Cefazolin (Antibiotic) Clinical Trial Eligibility Overview. Trial Name: NCT04288206 — N/A
Supracondylar Humerus Fractures Research Study Groups: Placebo control, Cefazolin prophylaxis
Supracondylar Humerus Fractures Clinical Trial 2023: Cefazolin Highlights & Side Effects. Trial Name: NCT04288206 — N/A
Cefazolin (Antibiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04288206 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment enrolling the elderly population?

"According to the study's guidelines, minors ranging from newborns to 18 years of age are eligible for enrollment."

Answered by AI

For what health issues is Cefazolin prophylaxis typically prescribed?

"Cefazolin prophylaxis is traditionally employed as a preventive measure for surgery. Yet, this therapeutic intervention can also combat skin and subcutaneous tissue bacterial infections, prophylactic measures against post-operative infection, and other related maladies."

Answered by AI

Is this trial recruiting participants presently?

"The clinicaltrials.gov registry reveals that this medical trial is still recruiting patients and was first posted on the 7th of January 2021 with its most recent update made on 8th April 2022."

Answered by AI

Who is eligible to join this experimental research?

"Eligibility for this medical trial necessitates that applicants are under 18 years of age and have an infection. 1200 people will ultimately be recruited into the experiment."

Answered by AI

To what extent is this experiment involving participants?

"Affirmative. As evidenced on clinicaltrials.gov, this research project is currently recruiting participants and was initially publicized on July 1st 2021. The team hopes to enrol 1200 patients from a single trial site by April 8th 2022."

Answered by AI

Has Cefazolin been tested as a form of preventive medicine in prior studies?

"At present, 17 clinical trials currently explore the use of Cefazolin prophylaxis. Of these studies, 2 are in phase 3 and they span 151 medical centres across Singapore and New South Wales."

Answered by AI
Recent research and studies
~277 spots leftby May 2025